Bromocriptine suppliers

Properties

Melting point:：

215-218° (dec)

alpha ：

D20 -195° (c = 1 in methylene chloride)

Boiling point:：

891.3±65.0 °C(Predicted)

Density ：

1.2734 (rough estimate)

refractive index ：

1.6400 (estimate)

pka：

pKa 4.90±0.05(80% MCS t = RT) (Uncertain)

Water Solubility ：

2.07mg/L(temperature not stated)

InChIKey：

OZVBMTJYIDMWIL-CCCBMRMVNA-N

SMILES：

N12[C@@H](CC(C)C)C(N3CCC[C@@]3([H])[C@]1(O)O[C@@](C(C)C)(NC(=O)[C@H]1CN([C@]3([H])CC4=C(NC5C=CC=C(C4=5)C3=C1)Br)C)C2=O)=O |&1:1,11,13,16,23,26,r|

CAS DataBase Reference：

25614-03-3(CAS DataBase Reference)

SecurityInformation

Symbol(GHS) ：

GHS07,GHS08

Signal word ：

Warning

Hazard statements ：

H361-H362-H302

Precautionary statements ：

P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P312-P330-P501-P201-P260-P263-P264-P270-P308+P313

Toxicity：

An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson’s disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, i.v.